Sickle Cell Anemia Therapeutics Market Analysis, Industry Insights, Report 2021-2027

Sickle cell anemia therapeutics include medication, blood transfusions, and sometimes a bone-marrow transplant. Sickle-cell diseases are types of blood disorders which are usually inherited genetically. Currently, hematopoietic stem cell transplant is the only curative therapy available for patients with sickle cell disease. However, hematopoietic stem cell transplant is a rigorous, time-consuming, potentially high-risk procedure; it is only used when the benefits of a cure outweigh the considerable risks of the procedure, and only when a suitable donor is available. One of the common types of sickle cell diseases is the sickle cell anemia.

Apply Here For The Sample Copy Of The Report: https://www.coherentmarketinsights.com/insight/request-sample/161

Therefore, growth of the sickle cell anemia therapeutics market is attributed to the increasing prevalence of sickle cell anemia, especially in the United States. Sickle cell disease is among the most common genetic diseases in the U.S. According to the Centers for Disease Control and Prevention (CDC), sickle cell disease affects around 70,000 to 100,000 people in the U.S. However, the exact number of people living with sickle cell disease in the U.S. is unknown. Thus, with the increasing prevalence of sickle cell anemia, the demand for sickle cell anemia therapeutics is also increasing in this region.

For example, in November 2019, the Food and Drug Administration (FDA) granted accelerated approval to voxelotor (Oxbryta, Global Blood Therapeutics) for adults and pediatric patients 12 years of age and older with sickle cell disease. Moreover, November 2019, FDA approved crizanlizumab-tmca (ADAKVEO, Novartis) to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. This in turn is expected to augment the growth of the sickle cell anemia therapeutics market in North America, especially in the U.S.

Sickle cell disease is common among people of Middle Eastern, African, and South Asian descent. Sickle cell anemia can have genotypic and phenotypic variants based on different mutations in hemoglobin genes. Sickle cell diseases, such as sickle cell anemia, are very common among Black or African Americans. According to the CDC, sickle cell disease occurs among about 1 out of every 365 Black or African-American births. Moreover, around 1 in 13 Black or African-American babies born with sickle cell trait. The increasing prevalence of the disease will increase the demand for prevention and treatment of sickle cell disease.

Buy This Premium Research Report: https://www.coherentmarketinsights.com/promo/buynow/161

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.